Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

Sorrento Therapeutics, Inc. Form 4 October 19, 2012										
FORM 4 UNITED				OMB A	PPROVAL					
Check this box) STATES SEC V	OMB Number:	3235-0287							
if no longer subject to Section 16. Form 4 or	MENT OF CH	Expires: Estimated burden ho response	urs per							
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Responses)										
1. Name and Address of Reportin AFTING ERNST-GUENT	ER Symb	suer Name and Ticker or Trading ol ento Therapeutics, Inc. [SRNE]	 Relationship of Reporting Person(s) to Issuer 							
(Last) (First)		te of Earliest Transaction	(Che	ck all applicabl	icable)					
C/O SORRENTO THERAI INC., 6042 CORNERSTON COURT WEST, SUITE B	(Mont PEUTICS, 10/12	th/Day/Year)	Officer (give title 10% Owner Officer (give title Other (specify below) below)							
(Street)	4. If A	Amendment, Date Original	6. Individual or Joint/Group Filing(Check							
SAN DIEGO, CA 92121	Filed(Month/Day/Year)	y/Year) Applicable Line) _X_ Form filed by 0 Form filed by N Person							
(City) (State)	(Zip) T	Sabla I. Nan Daningting Committies		f an Danaffair	Jun Orana d					
	1	Cable I - Non-Derivative Securities A			-					
1.Title of Security (Instr. 3)2. Transaction Dat (Month/Day/Year)	e 2A. Deemed Execution Date, i any (Month/Day/Year	Code Disposed of (D) r) (Instr. 8) (Instr. 3, 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
		Code V Amount (D) Price								
Reminder: Report on a separate lin	ne for each class of s	securities beneficially owned directly	-	ation of	SEC 1474					
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.SEC 1474 (9-02)										
Та		Securities Acquired, Disposed of, or calls, warrants, options, convertible		l						

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amou
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	iorDerivative	Expiration Date	Underlying Securi

Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Instr. 3 and 4)			
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo Nun Shai
Non-qualified stock option	\$ 0.16	10/17/2012		А	400,000		<u>(1)</u>	09/06/2022	Common Stock	400

Reporting Owners

Reporting Owner Name / Address		Relationships					
r g a a a a a a a	Director	10% Owner	Officer	Other			
AFTING ERNST-GUENTER C/O SORRENTO THERAPEUTICS, INC. 6042 CORNERSTONE COURT WEST, SUITE B SAN DIEGO, CA 92121	Х						
Signatures							
/s/ Henry Ji, Ph.D., Attorney-in-Fact for Ernst-Guen Afting	ter	10/19/2012					
**Signature of Reporting Person		Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/48 of the original number of shares subject to this option shall vest and become exercisable following each one-month period of service starting on September 6, 2012, subject to the reporting person's continued service on the issuer's board of directors on each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.